{"id":430,"date":"2025-12-16T03:15:24","date_gmt":"2025-12-16T03:15:24","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=430"},"modified":"2025-12-16T03:15:25","modified_gmt":"2025-12-16T03:15:25","slug":"china-bd-2025-genescience-and-yarrow-bioscience-rtw-entered-a-1-4-billion-usd-license-for-anti-tshr-antibody-gensci098-yb-101","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2025\/430.html","title":{"rendered":"[China BD 2025] GeneScience and Yarrow Bioscience (RTW) Entered a 1.4 Billion USD License for Anti-TSHR Antibody GenSci098 (YB-101)"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Announced Date: 2025-12-15 (December 15, 2025)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensor (Seller): Shanghai Scizeng Medical Technology, a subsidiary of Changchun GeneScience Pharmaceutical\u00a0 (China)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensee (Buyer): \u00a0Yarrow Bioscience, backed by RTW Investment (US)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Name: GenSci098, GS-098 (YB-101)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Modality: humanized  monoclonal antibody \uff08mAb\uff09<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Asset Target:  thyroid-stimulating hormone receptor (TSHR)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Potential Indication:  Graves\u2019 Disease and Thyroid Eye Disease<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Current Stage: <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Scope of Authority:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Agreement grants Yarrow Bioscience, Inc. exclusive global ex-China rights to develop and commercialize GS-098 (YB-101) for Graves\u2019 disease (GD) and thyroid eye disease (TED).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Payment Detail:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">GeneScience will receive:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">upfront payment of US$70 million, and near-term development milestone US$50 million, \u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">up to US$1.365 billion milestone payments,<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">10% plus royalties on potential future product sales in licensed territories.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Link:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Note:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Chinese Name<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Changchun GeneScience Pharmaceutical\u00a0, \u957f\u6625\u91d1\u8d5b\u751f\u7269<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Shanghai Scizeng Medical Technology, \u4e0a\u6d77\u8d5b\u589e\u533b\u7597<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2025-12-15 (December 15, 2025) Licensor (Seller): Shanghai Scizeng Medical Technology, a subsidiary of Changchun &hellip; <a title=\"[China BD 2025] GeneScience and Yarrow Bioscience (RTW) Entered a 1.4 Billion USD License for Anti-TSHR Antibody GenSci098 (YB-101)\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2025\/430.html\"><span class=\"screen-reader-text\">[China BD 2025] GeneScience and Yarrow Bioscience (RTW) Entered a 1.4 Billion USD License for Anti-TSHR Antibody GenSci098 (YB-101)<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-430","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/430","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=430"}],"version-history":[{"count":1,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/430\/revisions"}],"predecessor-version":[{"id":431,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/430\/revisions\/431"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=430"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=430"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=430"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}